More than 25 years' clinical experience in patient treatment
For long-term augmentation therapy in subjects with alpha1-proteinase inhibitor deficiency (phenotypes PiZZ, PiZ(null), Pi (null,null) and PiSZ) within the limits of moderate airflow obstruction (FEV1 35-60%) and the evaluation of the clinical condition (disability).
- Maintains protective levels of AAT in plasma.
- Good tolerability and safety in replacement therapy in patients with AAT deficiency-related emphysema.
Presentation: 1 g.
Storage conditions: storable for 2 years at room temperature (≤25ºC).
Grifols monitors the entire plasma derivatives production process from start to finish. All Grifols products are subjected to rigorous donor screening, testing and viral elimination (inactivation and removal) processes to enhance their quality and safety.
Grifols has been awarded the Quality Standards of Excellence Assurance and Leadership (QSEAL) by the Plasma Protein Therapeutics Association (PPTA).
This is only basic information.
Please see Summary of Product Characteristics, available at www.hpra.ie (use the "Find a Medicine" search option) for further information.
Grifols plasma-derived products are the result of a rigorous methodology, the latest technology and a highly qualified team of professionals.